MedTrace Logo

Stem Cell Therapy for Early Alzheimer's Disease

NCT06775964 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-04-20

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if stem cell therapy works to treat brain inflammation in adults. Inflammation in the brain may be involved in adults who have memory or thinking problems. The stem cells will be taken from participant's fat samples, processed and given back to participants, so they are their own donor. The main questions this trial aims to answer are:

* Does stem cell therapy reduce inflammation in the brain?
* Does stem cell therapy improve brain activity?
* Does stem cell therapy slow down progression to Alzheimer's disease?

Participants will:

* Have a small fat biopsy taken at a doctor's office to process stem cells
* Receive 4 infusions of stem cells, through a vein in the arm over 12 weeks
* Visit the clinic every 2-4 weeks for the first 4 months and then every 1-2 months for 8 months for checkups and tests

Conditions

  • Cognitive Dysfunction

Interventions

BIOLOGICAL

adMSC

IV-infusion of autologous, adipose-derived, Mesenchymal Stem Cells (adMSCs), of approximately 2x10(8) adMSCs in 250mL saline.

Sponsors & Collaborators

  • Weston Brain Institute

    collaborator OTHER

  • Paul E Schulz

    lead OTHER

Principal Investigators

  • Paul E Schulz, MD · The University of Texas Health Science Center, Houston

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-11
Primary Completion
2027-01-31
Completion
2028-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06775964 on ClinicalTrials.gov